AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

ASX:IVXInvion Stock Price, Forecast & News

0.0080
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.01
Now: A$0.01
A$0.01
50-Day Range
A$0.01
MA: A$0.01
A$0.01
52-Week Range
A$0.01
Now: A$0.01
A$0.03
Volume471,000 shs
Average VolumeN/A
Market Capitalization$44.00 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Invion Limited, a clinical-stage drug development company, develops treatments for chronic inflammatory and autoimmune diseases in Australia and the United States. Its drug candidates in phase II clinical trials include INV102, a beta blocker to treat chronic inflammatory airway diseases, such as asthma and chronic obstructive pulmonary disease; and INV104, a leukotriene receptor antagonist that reduces inflammation, constriction of the airways, and build-up of mucus in the lungs. The company has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers. Invion Limited is based in East Kew, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9081 6005

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.57 million
Cash FlowA$0.00 per share
Book ValueA$0.00 per share

Profitability

Miscellaneous

EmployeesN/A
Outstanding Shares5,500,610,048
Market Cap$44.00 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IVX News and Ratings via Email

Sign-up to receive the latest news and ratings for IVX and its competitors with MarketBeat's FREE daily newsletter.

Invion (ASX:IVX) Frequently Asked Questions

How has Invion's stock been impacted by COVID-19 (Coronavirus)?

Invion's stock was trading at A$0.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IVX stock has increased by 14.3% and is now trading at A$0.01. View which stocks have been most impacted by Coronavirus.

Has Invion been receiving favorable news coverage?

Press coverage about IVX stock has been trending negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Invion earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Invion.

Who are some of Invion's key competitors?

What other stocks do shareholders of Invion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invion investors own include Walt Disney (DIS), Centurylink (CTL), Carlisle Companies (CSL), Cape Lambert Resources (CFE), Camtek (CAMT), Boston Properties (BXP), BioSpecifics Technologies (BSTC), BJ's Restaurants (BJRI), Banco Bradesco (BBD) and Aggreko (AGK).

Who are Invion's key executives?

Invion's management team includes the following people:
  • Dr. Gregory Royce Collier, MD, CEO & Exec. Director (Age 60)
  • Ms. Melanie Farris, Head of Operations & Company Sec.
  • Dr. Mitchell Glass, Exec. VP of R&D, Chief Medical Officer and Exec. Director (Age 66)
  • Mr. Tom Coogan, Consultant
  • Dr. Dean Naylor, Head of Intellectual Property Devel.

What is Invion's stock symbol?

Invion trades on the ASX under the ticker symbol "IVX."

What is Invion's stock price today?

One share of IVX stock can currently be purchased for approximately A$0.01.

How big of a company is Invion?

Invion has a market capitalization of $44.00 million and generates $4.57 million in revenue each year.

What is Invion's official website?

The official website for Invion is www.inviongroup.com.

How can I contact Invion?

The company can be reached via phone at 61 3 9081 6005.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.